SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the 25th Annual Needham Growth Conference on Wednesday, January 11, 2023 and will host a fireside chat at 1:30 pm ET. A webcast and replay of the fireside chat will be available at ir.accolade.com.
About Accolade, Inc.
Accolade (Nasdaq: ACCD) provides millions of people and their families with an exceptional healthcare experience that is personal, data driven and value based to help every person live their healthiest life. Accolade solutions combine virtual primary care, mental health support and expert medical opinion services with intelligent technology and best-in-class care navigation. Accolade's Personalized Healthcare approach puts humanity back in healthcare by building relationships that connect people and their families to the right care at the right time to improve outcomes, lower costs and deliver consumer satisfaction. Accolade consistently receives consumer satisfaction ratings over 90%. For more information, visit www.accolade.com.
Investor Contact:
Todd Friedman, Investor Relations, This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Accolade
| Last Trade: | US$6.85 |
| Daily Change: | 3.41 99.13 |
| Daily Volume: | 86,966,969 |
| Market Cap: | US$551.700M |
January 08, 2025 November 13, 2024 October 08, 2024 August 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
